Respiratory syncytial virus vaccine development

Vaccine

Volumn 20, Issue SUPPL. 1, 2001, Pages

  Crowe Jr , James E ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Parainfluenza virus (PIV); Respiratory syncytial virus (RSV); Vaccines

Indexed keywords

DNA VACCINE; FORMALDEHYDE; INACTIVATED VACCINE; LIVE VACCINE; PROTEIN SUBUNIT; RESPIRATORY SYNCYTIAL VIRUS VACCINE; VIRUS PROTEIN; VIRUS VECTOR;

ARTICLE; CLINICAL TRIAL; HUMAN; IMMATURITY; IMMUNITY; IMMUNIZATION; INFANT; INFECTION PREVENTION; NONHUMAN; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RNA VIRUS INFECTION; VIRUS ATTENUATION; VIRUS INFECTION;

EID: 0035888291     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(01)00287-0     Document Type: Short Survey

References (57)

1. Respiratory syncytial virus infection in inbred mice
2. Primary respiratory syncytial virus infection in mice
3. The pathogenesis of respiratory syncytial virus infection in cotton rats
4. Evaluation of two live, cold-passaged, temperature-sensitive respiratory syncytial virus vaccines in chimpanzees and in human adults, infants, and children
5. Live subgroup B respiratory syncytial virus vaccines that are attenuated, genetically stable, and immunogenic in rodents and non-human primates
6. Evaluation of a live, cold-passaged temperature-sensitive, respiratory syncytial virus (RSV) vaccine in infancy
7. Risk of respiratory syncytial virus infection for infants from low-income families in relationship to age, sex, ethnic group, and maternal antibody level
8. Neonatal respiratory syncytial virus infection
9. Viral respiratory infections in the institutionalized elderly: Clinical and epidemiologic findings
10. Passively-acquired antibodies suppress humoral but not cell-mediated immunity in mice immunized with live attenuated RSV vaccines
11. Cold-passaged, temperature sensitive mutants of human respiratory syncytial virus (RSV) are highly attenuated, immunogenic, and protective in seronegative chimpanzees, even when RSV antibodies are infused shortly before immunization
12. Passive protection against respiratory syncytial virus disease in infants: The role of maternal antibody
13. Immunity to and frequency of reinfection with respiratory syncytial virus
14. Risk of primary infection and reinfection with respiratory syncytial virus
15. Relation of serum antibody to glycoproteins of respiratory syncytial virus with immunity to infection in children
16. Respiratory syncytial virus disease in infants despite poor administration of antigenic inactivated vaccine
17. An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine
18. Pathogenesis of respiratory syncytial virus vaccine-augmented pathology
19. Sequential annual administration of purified fusion protein vaccine against respiratory syncytial virus in children with cystic fibrosis
20. Safety and immunogenicity of a purified F protein respiratory syncytial virus (PFP-2) vaccine in seropositive children with bronchopulmonary dysplasia
21. Safety and immunogenicity of a respiratory syncytial virus subunit vaccine (PFP-2) in ambulatory adults over age 60
22. Maternal immunization against viral disease
23. Cytotoxic T cells clear virus but augments lung pathology in mice infected with respiratory syncytial virus
24. Respiratory syncytial virus illnesses in human immunodeficiency virus and non-infected children
25. Role of T-lymphocyte subsets in the pathogenesis of primary infection and re-challenge with respiratory syncytial virus in mice
26. Respiratory syncytial virus (RSV) F, G, M2 (22K), and N proteins each induce resistance to RSV challenge, but resistance induced by M2 and N proteins is relatively short-lived
27. Group-specific serum antibody responses in children with primary and recurrent respiratory syncytial virus infections
28. Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children
29. Experimental respiratory syncytial virus infection in adults. Possible mechanisms of resistance to infection and illness
30. The immunologic response to infection with respiratory syncytial virus in infants
31. Evaluation of a live, attenuated recombinant respiratory syncytial virus vaccine in infants
32. Production of infectious human respiratory syncytial virus from cloned cDNA confirms an essential role for the transcription elongation factor from the 5′ proximal open-reading frame of the M2 mRNA in gene expression and provides a capability for vaccine development
33. Acquisition of the ts phenotype by a chemically mutagenized cold-passaged human respiratory syncytial virus vaccine candidate results from the acquisition of a single mutation in the polymerase L gene
34. Nucleotide sequence analysis of the respiratory syncytial virus (RSV) subgroup A cold-passaged (cp), temperature sensitive (ts) cpts-248/404 live attenuated virus vaccine candidate
35. Effect of co-expression of interleukin-2 by recombinant respiratory syncytial virus on virus replication, immunogenicity, and production of other cytokines
36. Recombinant respiratory syncytial virus that does not express the NS1 or M2-2 protein is highly attenuated and immunogenic in chimpanzees
37. Replacement of the F and G proteins of respiratory syncytial virus (RSV) subgroup A with those of subgroup B generates chimeric live attenuated RSV subgroup B vaccine candidates
38. A live attenuated recombinant chimeric parainfluenza virus (PIV) candidate vaccine containing the hemagglutinin-neuraminidase and fusion glycoproteins of PIV-1 and the remaining proteins from PIV-3 induces resistance to PIV-1 even in animals immune to PIV-3
39. Chimeric bovine respiratory syncytial virus with glycoprotein gene substitutions from human respiratory syncytial virus (HRSV): Effects on host-range and evaluation as a live-attenuated HRSV vaccine
40. A recombinant human parainfluenza virus type 3 (PIV-3) in which the nucleocapsid N protein has been replaced by that of bovine PIV-3 is attenuated in primates
41. Human parainfluenza virus type 3 (PIV-3) expressing the hemagglutinin protein of measles virus provides a potential method for immunization against measles virus and PIV-3 in early infancy
42. A comparison in chimpanzees of the immunogenicity and efficacy of live attenuated respiratory syncytial virus (RSV) temperature-sensitive mutant vaccines and vaccinia virus recombinants that express the surface glycoproteins of RSV
43. Immunogenicity of recombinant adenovirus-respiratory syncytial virus vaccines with adenovirus types 4, 5, and 7 vectors in dogs and a chimpanzee
44. Priming and boosting immunity to respiratory syncytial virus by recombinant replication defective vaccinia virus MVA
45. Enhanced pulmonary histopathology is observed in cotton rats immunized with formalin-inactivated respiratory syncytial virus (RSV) or purified F glycoprotein and challenged with RSV 3-6 months after immunization
46. Cotton rats previously immunized with a chimeric RSV FG glycoprotein develop enhanced pulmonary pathology when infected with RSV, a phenomenon not encountered following immunization with vaccinia RSV recombinants or RSV
47. Safety and immunogenicity of a purified F protein respiratory syncytial virus (PFP-2) vaccine in seropositive children with bronchopulmonary dysplasia
48. Purified fusion protein vaccine protects against lower respiratory tract illness during respiratory syncytial virus season in children with cystic fibrosis
49. Safety and immunogenicity of a respiratory syncytial virus subunit vaccine (PFP-2) in the institutionalized elderly
50. Evaluation of the live attenuated cpts-248/404 RSV vaccine in combination with a subunit RSV vaccine (PFP-2) in healthy young and older adults
51. Induction of protective immunity in rodents by vaccination with a prokaryotically expressed recombinant fusion protein containing a respiratory syncytial virus G protein fragment
52. Protection against respiratory syncytial virus infection by DNA immunization
53. Bovine respiratory syncytial virus protects cotton rats against human respiratory syncytial virus infection
54. A peptide mimic of a protective epitope of respiratory syncytial virus selected from a combinatorial library induces virus-neutralizing antibodies and reduces viral load in vivo
55. The immunostimulating complex (ISCOM) is an efficient mucosal delivery system for respiratory syncytial virus (RSV) envelope antigens inducing high local and systemic antibody responses
56. Formulation of the purified fusion protein of respiratory syncytial virus with the saponin QS-21 induces protective immune responses in BALB/c mice that are similar to those generated by experimental infection
57. Adjuvants influence the quantitative and qualitative immune response in BALB/c mice immunized with respiratory syncytial virus FG subunit vaccine